# US 2016/0355885 A1 · Gene methylation based colorectal cancer diagnosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355885 A1
- Document ID: US20160355885A1
- Status: Published application
- Kind: A1
- Application number: 15/106,578
- Filed: 2014-12-19
- Published: 2016-12-08
- Earliest claimed: 2013-12-20
- Assignees: Ait Austrian Institute of Technology GmbH; Tecnet Equity NO Technologiebeteiligungs-Invest GmbH
- Applicants: Ait Austrian Institute of Technology GmbH; Tecnet Equity Nö Technologiebeteiligungs-Invest GmbH
- Inventors: Andreas WEINHÄUSEL; Walter PULVERER
- Web page: https://patentgrep.com/patent/US20160355885A1

## CPC

- C12Q 1/6886: for cancer (immunoassay for cancer G01N33/575)
- C12Q 2600/154: Methylation markers
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The invention provides method of identifying a colorectal cancer in a sample comprising DNA from a subject, determining the methylation status of one or more of the genes selected from BOLL, CDX1, CLIC4, DCC, ESR1, GATA4, GDNF, HLA-G, JUB, MYOD1, NKX2-1, PENK, PITX2, PTGS2, RARB, S100A2, SALL3, SEZ6L, SFRP2, SPARC, TCEB2, TFPI2, THBD, TJP2, TMEFF2, TP53, TWIST1, WT1 or combinations thereof and comparing the methylation status with a control, thereby identifying colorectal cancer DNA in the sample and means for performing the inventive method.

## Claims

### Claim at position 1

-15. (canceled)

### Claim 16

A method of identifying a colorectal cancer in a sample comprising:
obtaining DNA from a subject;
determining a methylation status of one or more genes further defined as PTGS2, TFPI2, TWIST1, TMEFF2, BOLL, CDX1, CLIC4, DCC, ESR1, GATA4, GDNF, HLA-G, JUB, MYOD1, NKX2-1, PENK, PITX2, RARB, S100A2, SALL3, SEZ6L, SFRP2, SPARC, TCEB2, THBD, TJP2, TP53, or WT1; and
comparing the methylation status with a control, thereby identifying colorectal cancer DNA in the sample.

### Claim 17 (depends on 16)

The method of claim 16, wherein the one or more genes comprises a marker of one of the following groups:
a) BOLL, CDX1, CLIC4, DCC, ESR1, GATA4, GDNF, HLA-G, JUB, MYOD1, NKX2-1, PENK, PITX2, PTGS2, RARB, S100A2, SALL3, SEZ6L, SFRP2, SPARC, TCEB2, TFPI2, THBD, TJP2, TMEFF2, TP53, TWIST1, or WT1;
b) ESR1, TFPI2, WT1, TMEFF2, PENK, MYOD1, TWIST1, DCC, PTGS2, TJP2, SPARC, PITX2, SEZ6L, TP53, GDNF, CDX1, CLIC4, SFRP2, HLA-G, GATA4, BOLL, THBD, RARB, NKX2-1, SALL3, or JUB;
c) TFPI2 or TJP2;
d) TMEFF2, PITX2, TWIST1, ESR1, BOLL, TFPI2, WT1, GDNF, HLA-G, PENK, SEZ6L, SFRP2, TCEB2 and RARB;
e) TMEFF2, TWIST1, PITX2 and TFPI2;
f) TWIST1, TMEFF2, ESR1, WT1, PITX2, TFPI2, HLA-G, PENK, BOLL, DCC, TP53, GATA4, GDNF, RARB, CLIC4, SEZ6L, SFRP2, PTGS2, THBD, TJP2, SPARC, TCEB2, MYOD1, and S100A2;
g) TFPI2, TMEFF2, TWIST1, ESR1, PITX2, DCC, WT1, SEZ6L, BOLL and SFRP2;
h) TFPI2, DCC, PTGS2, TJP2, and PITX2;
i) TFPI2, DCC, PTGS2, and TJP2;
j) TFPI2, DCC, and PTGS2;
k) TFPI2, PTGS2;
l) TMEFF2, PITX2, TWIST1, SFRP2, RARB, ZNF256, SPARC, DAPK1, CALCA, and S100A2;
m) TMEFF2, PITX2, TWIST1, SFRP2, ZNF256, SPARC, and DAPK1;
n) TMEFF2, PITX2, TWIST1, SPARC, and S100A2;
o) TMEFF2 and TWIST1;
p) GATA4, WT1, TFPI2, SEZ6L, TMEFF2, DCC, BOLL, PITX2, and GDNF;
q) TMEFF2, PITX2, and TWIST1;
r) TMEFF2, TWIST1, PTX2, and S100A2;
s) DAPK1, TMEFF2, PITX2, S100A2, ZNF256, RARB, and SFRP2;
t) DAPK1, TMEFF2, PITX2, S100A2, SPARC, CALCA, TWIST1, ZNF256, RARB, and SFRP2;
or a group of markers comprising at least 50%, preferably at least 60%, at least 70%, at least 80%, at least 90%, 100% of the genes of any one of the above groups a) to t), preferably wherein, for a given group, at least 2 genes are represented.

### Claim 18 (depends on 16)

The method of claim 16, wherein the one or more genes comprise TMEFF2, ESR1, TWIST1; or a combination of TMEFF2 and ESR1; a combination of TMEFF2 and TWIST1; or a combination of ESR1 and TWIST1.

### Claim 19 (depends on 16)

The method of claim 16, wherein the one or more genes comprise TFPI2 and/or TJP2.

### Claim 20 (depends on 16)

The method of claim 16, wherein the one or more genes comprise one or more of BOLL, GDNF, HLA-G, PENK, PITX2, RARB, SEZ6L, SFRP2, and TMEFF2.

### Claim 21 (depends on 16)

The method of claim 16, wherein the one or more genes comprise one or more of ESR1, TFPI2, WT1, and TWIST1.

### Claim 22 (depends on 16)

The method of claim 16, wherein the step of determining the methylation status comprises a methylation specific PCR analysis, methylation specific digestion analysis, preferably with hybridization analysis to non-digested or digested fragments, or PCR amplification analysis of non-digested or digested fragments, or bisulfite deamination followed by identification of methylated C changes, preferably by PCR or hybridization.

### Claim 23 (depends on 16)

The method of claim 16, comprising comparing the methylation status with the status of a confirmed colorectal cancer positive and/or negative state.

### Claim 24 (depends on 16)

The method of claim 16, wherein the sample of the subject is a colorectal tissue sample, preferably of a colorectal polyp, or a blood or serum sample, especially a blood, plasma or serum sample taken from the circulatory system of the subject.

### Claim 25 (depends on 16)

The method of claim 16, wherein the control sample is a colorectal tissue sample, a sample adjacent to a colorectal polyp or cancer tissue, or a blood, plasma or serum sample, especially a sample comprising blood cells, such as PBMCs.

### Claim 26 (depends on 16)

The method of claim 16, wherein the methylation status of said genes is determined in an upstream region of the open reading frame of the marker genes, in particular a promoter region; or in a) a genetic locus defined by the primer pairs of SEQ ID NO: 1 to 96 and/or b) the chromosomal locus as identified in table 1; or c) a locus within at most 1000 nucleotides in length distanced from said locus a) or b).

### Claim 27

A set of nucleic acid primers or hybridization probes being specific for a potentially methylated region of marker genes being suitable to diagnose or predict colorectal cancer, with the set comprising probes or primers for genes:
a) BOLL, CDX1, CLIC4, DCC, ESR1, GATA4, GDNF, HLA-G, JUB, MYOD1, NKX2-1, PENK, PITX2, PTGS2, RARB, S100A2, SALL3, SEZ6L, SFRP2, SPARC, TCEB2, TFPI2, THBD, TJP2, TMEFF2, TP53, TWIST1 and WT1;
b) ESR1, TFPI2, WT1, TMEFF2, PENK, MYOD1, TWIST1, DCC, PTGS2, TJP2, SPARC, PITX2, SEZ6L, TP53, GDNF, CDX1, CLIC4, SFRP2, HLA-G, GATA4, BOLL, THBD, RARB, NKX2-1, SALL3 and JUB;
c) TFPI2 and TJP2;
d) TMEFF2, PITX2, TWIST1, ESR1, BOLL, TFPI2, WT1, GDNF, HLA-G, PENK, SEZ6L, SFRP2, TCEB2 and RARB;
e) TMEFF2, TWIST1, PITX2 and TFPI2;
f) TWIST1, TMEFF2, ESR1, WT1, PITX2, TFPI2, HLA-G, PENK, BOLL, DCC, TP53, GATA4, GDNF, RARB, CLIC4, SEZ6L, SFRP2, PTGS2, THBD, TJP2, SPARC, TCEB2, MYOD1 and S100A2;
g) TFPI2, TMEFF2, TWIST1, ESR1, PITX2, DCC, WT1, SEZ6L, BOLL and SFRP2;
h) TFPI2, DCC, PTGS2, TJP2, and PITX2;
i) TFPI2, DCC, PTGS2, and TJP2;
j) TFPI2, DCC, and PTGS2;
k) TFPI2 and PTGS2;
l) TMEFF2, PITX2, TWIST1, SFRP2, RARB, ZNF256, SPARC, DAPK1, CALCA, and S100A2;
m) TMEFF2, PITX2, TWIST1, SFRP2, ZNF256, SPARC, and DAPK1;
n) TMEFF2, PITX2, TWIST1, SPARC, and S100A2;
o) TMEFF2 and TWIST1;
p) GATA4, WT1, TFPI2, SEZ6L, TMEFF2, DCC, BOLL, PITX2, and GDNF;
q) TMEFF2, PITX2, and TWIST1;
r) TMEFF2, TWIST1, PTX2, and S100A2;
s) DAPK1, TMEFF2, PITX2, S100A2, ZNF256, RARB, and SFRP2;
t) DAPK1, TMEFF2, PITX2, S100A2, SPARC, CALCA, TWIST1, ZNF256, RARB, and SFRP2;
or probes or primers for at least 50%, preferably at least 60%, at least 70%, at least 80%, at least 90%, 100% of the genes of anyone of the above a) to t), with the proviso that at least 2 genes are represented, and any of these sets comprises not more than 350 probes or primer pairs.

### Claim 28 (depends on 27)

The set of claim 27, wherein the primer pairs and probes are specific for a methylated upstream region of the open reading frame of the marker genes, in particular a promoter region; or specific for a) a genetic locus defined by the primer pairs of SEQ ID NO: 1 to 96 and/or b) the chromosomal locus as identified in table 1; or c) a locus within at most 1000 nucleotides in length distanced from said locus a) or b).

### Claim 29 (depends on 28)

The set of claim 28, wherein the probes or primers are of SEQ ID NOs: 1 to 96.

### Claim 30 (depends on 27)

The set of claim 27, wherein the set is provided in a kit together with a methylation specific restriction enzyme and/or a reagent for bisulfite nucleotide deamination; and/or wherein the set comprises probes on a microarray.
